Overactive bladder treatment: application of methylene blue to improve the injection technique of onabotulinum toxin A

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–178.
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188:2455–2463.
   PubMed Web of Science ®Google Scholar
• Dugan E, Cohen SJ, Bland DR, et al. The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc. 2000;48:413–416.
   PubMed Web of Science ®Google Scholar
• Zorn BH, Montgomery H, Pieper K, et al. Urinary incontinence and depression. J Urol. 1999;162:82–84.
   PubMed Web of Science ®Google Scholar
• Milsom I, Stewart W, Thuroff J. The prevalence of overactive bladder. Am J Manag Care. 2000;6:S565–S573.
   PubMed Web of Science ®Google Scholar
• Phe V, Wachter S. d, Roupret M, et al. How to define a refractory idiopathic overactive bladder? Neurourol Urodyn. 2015;34:2–11.
   PubMed Web of Science ®Google Scholar
• Lucas MG, Bosch RJL, Burkhard FC, et al. EAU guidelines on surgical treatment of urinary incontinence. Actas Urol Esp. 2013;37:459–472.
   PubMed Web of Science ®Google Scholar
• Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014;65:981–990.
   PubMed Web of Science ®Google Scholar
• Mangera A, Andersson K-E, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol. 2011;60:784–795.
   PubMed Web of Science ®Google Scholar
• Tincello DG, Kenyon S, Abrams KR, et al. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol. 2012;62:507–514.
   PubMed Web of Science ®Google Scholar
• Chapple C, Sievert K-D, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64:249–256.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189:2186–2193.
   PubMed Web of Science ®Google Scholar
• Hubler J, Szanto A, Konyves K. Methylene blue as a means of treatment for priapism caused by intracavernous injection to combat erectile dysfunction. Int Urol Nephrol. 2003;35:519–521.
   PubMedGoogle Scholar
• Lucas MG, Bosch RJL, Burkhard FC, et al. EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol. 2012;62:1130–1142.
   PubMed Web of Science ®Google Scholar
• Veenboer PW, Bosch JL, Ruud H. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol. 2014;191:1003–1008.
   PubMed Web of Science ®Google Scholar
• Al-zahrani AA, Elzayat EA, Gajewski JB. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol. 2011;185:981–986.
   PubMed Web of Science ®Google Scholar
• Gaziev G, Topazio L, Iacovelli V, et al. Percutaneous Tibial Nerve Stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol. 2013;13:61.
   PubMed Web of Science ®Google Scholar
• van Ermengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as ‘Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus’ in Zeitschrift fur Hygiene und Infektionskrankheiten 26: 1-56, 1897. Zeitschr f Hygiene. 1979;1:701–719.
   Google Scholar
• Andersson K-E. New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. Ther Clin Risk Manag. 2013;9:161–170.
   PubMed Web of Science ®Google Scholar
• Schurch B, Seze M, de Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200.
   PubMed Web of Science ®Google Scholar
• Karsenty G, Denys P, Amarenco G, et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol. 2008;53:275–287.
   PubMed Web of Science ®Google Scholar
• Apostolidis A, Popat R, Yiangou Y, et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol. 2005;174:977–983.
   PubMed Web of Science ®Google Scholar
• Karsenty G, Carsenac A, Boy S, et al. 890 botulinum toxin-a (BTA) in the treatment of neurogenic detrusor overactivity incontinence (NDOI): a prospective randomized study to compare 30 vs. 10 injection sites. Eur Urol Suppl. 2007;6:245.
   Web of Science ®Google Scholar
• Cox L, Cameron AP. Onabotulinumtoxin A for the treatment of overactive bladder. Res Rep Urol. 2014;6:79–89.
   PubMedGoogle Scholar
• Kuo H-C. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol. 2007;178:1359–1363.
   PubMed Web of Science ®Google Scholar
• Mahajan ST, Kenton K, Brubaker L. Cystoscopic intra-detrusor botulinum A toxin injection for the treatment of detrusor overactivity incontinence. J Urol. 2006;175(Suppl):539.
   Web of Science ®Google Scholar
• Landman BWM, Van Capelle JW. Intravesical Botox injections in children with a idhiopatic overactive bladder. Eur Urol Suppl. 2009;8:169.
   Web of Science ®Google Scholar
• Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–2422.
   PubMed Web of Science ®Google Scholar
• van der Horst C, Stuebinger H, Seif C, et al. Priapism: etiology, pathophysiology and management. Int Braz J Urol. 2003;29:391–400.
   PubMedGoogle Scholar